Leerink Partners analyst Thomas Smith has maintained their bullish stance on VRDN stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Thomas Smith’s rating is based on several promising developments within Viridian Therapeutics’ clinical pipeline and their adherence to projected timelines. The company is on track to submit a Biologics License Application (BLA) for veligrotug (VRDN-001) in the treatment of thyroid eye disease (TED) by the second half of 2025, with a potential market launch in 2026. This submission is supported by positive Phase 3 study results and a robust safety database from ongoing trials.
Additionally, Viridian’s other pipeline candidates, such as SC VRDN-003 and the FcRn inhibitors VRDN-006 and VRDN-008, are progressing well. The anticipated results and submissions for these candidates suggest a strong competitive position in the TED market, particularly against existing treatments like Tepezza. The company’s strategic advancements and potential for best-in-class profiles underscore the Buy rating, as they are poised to capture significant market share in a multi-billion dollar industry.
In another report released yesterday, Citizens JMP also maintained a Buy rating on the stock with a $38.00 price target.
VRDN’s price has also changed dramatically for the past six months – from $24.270 to $12.030, which is a -50.43% drop .